Another May 2021 multicenter analysis of patients with NSCLC and PD-L1 expression ≥50% who progressed on first line pembrolizumab monotherapy found that those patients who received local ablative treatments lived longer after progressing than those who switched systemic therapy or continued on pembrolizumab alone (overall survival of 13.9 months versus 8.0 months versus 8.2 months, respectively) [31]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.